ARHGDIA (Rho GDP dissociation inhibitor alpha) is a critical regulator of Rho GTPase homeostasis that functions as a guanine nucleotide dissociation inhibitor (GDI) 1. It maintains Rho proteins such as RAC1, CDC42, and RHOA in an inactive GDP-bound cytosolic state and mediates their extraction from membranes, thereby controlling their activation and cellular localization 2. ARHGDIA plays distinct roles across pathologies: in cancer, reduced expression promotes cell proliferation, migration, and invasion through enhanced Rho GTPase activation. ARHGDIA is downregulated in gliomas and hepatocellular carcinoma, correlating with poor prognosis and metastatic potential 34. In medulloblastoma, the miR-497/ARHGDIA axis regulates migration and invasion 5. Conversely, ARHGDIA mutations cause steroid-resistant nephrotic syndrome (SRNS) by abrogating GTPase binding, leading to excessive RAC1 and CDC42 activation and abnormal podocyte migration 6. Recent studies reveal ARHGDIA functions in the TRPV4-RhoA-RhoGDI1 axis to regulate vascular smooth muscle function and blood pressure 2. Post-transcriptional regulation of ARHGDIA by PCBP2 and microRNAs (miR-151-5p, miR-16) modulates its expression in gliomas 7. ARHGDIA represents a potential prognostic biomarker and therapeutic target across multiple disease contexts.